Can BACE1 Inhibition Mitigate Early Axonal Pathology in Neurological Diseases?

Xiaoxin Yan, Chao Ma, Wei-Ping Gai, Huaibin Cai, Xue-Gang Luo

    Research output: Contribution to journalReview articlepeer-review

    16 Citations (Scopus)


    β-Secretase-1 (BACE1) is the rate-limiting enzyme for the genesis of amyloid-β (Aβ) peptides, the main constituents of the amyloid plaques in the brains of Alzheimer's disease (AD) patients. BACE1 is being evaluated as an anti-Aβ target for AD therapy. Recent studies indicate that BACE1 elevation is associated with axonal and presynaptic pathology during plaque development. Evidence also points to a biological role for BACE1 in axonal outgrowth and synapse formation during development. Axonal, including presynaptic, pathology exists in AD as well as many other neurological disorders such as Parkinson's disease, epilepsy, stroke, and trauma. In this review, we discuss pharmaceutical BACE1 inhibition as a therapeutic option for axonal pathogenesis, in addition to amyloid pathology. We first introduce the amyloidogenic processing of amyloid-β protein precursor and describe the normal expression pattern of the amyloidogenic proteins in the brain, with an emphasis on BACE1. We then address BACE1 elevation relative to amyloid plaque development, followed by updating recent understanding of a neurotrophic role of BACE1 in axon and synapse development. We further elaborate the occurrence of axonal pathology in some other neurological conditions. Finally, we propose pharmacological inhibition of excessive BACE1 activity as an option to mitigate early axonal pathology occurring in AD and other neurological disorders.

    Original languageEnglish
    Pages (from-to)705-718
    Number of pages14
    JournalJournal of Alzheimer's Disease
    Issue number4
    Publication statusPublished - 2014


    • Aging
    • Alzheimer's disease
    • Anti-amyloid therapy
    • Dementia
    • Dystrophic neurites
    • Neurodegenerative disorders
    • Neuroplasticity
    • Senile plaques
    • Synaptic dysfunction


    Dive into the research topics of 'Can BACE1 Inhibition Mitigate Early Axonal Pathology in Neurological Diseases?'. Together they form a unique fingerprint.

    Cite this